Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TM5614 plus paclitaxel for cutaneous angiosarcoma after paclitaxel failure
jRCT2021230016Phase 2Active, not recruiting
- Sponsor
- Renascience
- Start
- Oct 2023
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of TM5614 and paclitaxel in cutaneous angiosarcoma, sponsored by Renascience. Primary endpoint: Objective response rate at 28 weeks. Started Oct 2023; status: active, not recruiting.
02
Drugs
TM5614paclitaxel
03
Conditions
cutaneous angiosarcoma
Beyond the preview
Go deeper on jRCT2021230016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021230016.